Related Experiment Video
Updated: Aug 14, 2026
06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 19, 2013
Nonandrogenic mediators of prostatic growth
1Department of Urology, University of Pittsburgh, Pennsylvania 15213, USA. konetybr@msx.upmc.edu
Hematology/Oncology Clinics of North America
|August 30, 2001
Summary
Androgens control prostate growth, but other factors also influence it. This review explores key nonandrogenic mediators and their pathways in prostate development.
Area of Science:
- Urology
- Endocrinology
- Cell Biology
Background:
- Prostate growth and development are traditionally linked to androgens.
- Alternative signaling pathways also regulate prostate biology.
- Understanding these nonandrogenic factors is crucial for comprehensive prostate research.
Purpose of the Study:
- To identify and discuss major nonandrogenic mediators of prostate growth.
- To review the signaling pathways utilized by these mediators.
- To provide a consolidated overview of factors beyond androgens influencing prostatic development.
Main Methods:
- Literature review of scientific articles.
- Analysis of studies investigating prostate growth regulation.
- Synthesis of information on nonandrogenic factors and their mechanisms.
Main Results:
- Several nonandrogenic factors significantly influence prostate growth.
- These factors operate through distinct molecular and cellular pathways.
- Key mediators include growth factors, cytokines, and other signaling molecules.
Conclusions:
- Nonandrogenic mediators play a significant role in prostate growth and development.
- Targeting these alternative pathways may offer new therapeutic strategies.
- Further research into these mediators is warranted for a complete understanding of prostate biology.
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...